The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 04, 2020
Filed:
Dec. 18, 2015
Applicant:
Galderma Research & Development, Biot, FR;
Inventors:
Branislav Musicki, Nice, FR;
Claire Bouix-Peter, Vallauris, FR;
Gilles Ouvry, Biot, FR;
Etienne Thoreau, Saint Vallier de Thiey, FR;
Assignee:
GALDERMA RESEARCH & DEVELOPMENT, Biot, FR;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/06 (2006.01); C07D 405/14 (2006.01); C07D 215/36 (2006.01); C07D 231/56 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 403/04 (2006.01); C07D 403/06 (2006.01); C07D 405/04 (2006.01); C07D 405/12 (2006.01); C07D 407/04 (2006.01); C07D 409/04 (2006.01); C07D 409/06 (2006.01); C07D 417/06 (2006.01); C07D 471/10 (2006.01); C07D 209/34 (2006.01); C07D 307/79 (2006.01); C07D 405/06 (2006.01); A61P 17/10 (2006.01); A61P 17/06 (2006.01); A61P 17/04 (2006.01); C07D 401/14 (2006.01);
U.S. Cl.
CPC ...
C07D 413/06 (2013.01); A61P 17/04 (2018.01); A61P 17/06 (2018.01); A61P 17/10 (2018.01); C07D 209/34 (2013.01); C07D 215/36 (2013.01); C07D 231/56 (2013.01); C07D 307/79 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 405/04 (2013.01); C07D 405/06 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/04 (2013.01); C07D 409/04 (2013.01); C07D 409/06 (2013.01); C07D 417/06 (2013.01); C07D 471/10 (2013.01);
Abstract
Tetrahydroquinoline sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma (RORγt) are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of RORγt receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.